2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
40
Colorectal Neoplasms
25
Colonic Neoplasms
10
Brain Neoplasms
8
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Neoplasm Metastasis
6
Rectal Neoplasms
5
Skin Neoplasms
4
Lung Neoplasms
3
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Digestive System Neoplasms
2
Thyroid Neoplasms
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Solid Tumors
1
Solid Tumor
1
Skin Diseases
1
Recurrence
1
Rectal Diseases
1
Neurofibromatosis 1
1
Multiple Myeloma
1
Lymphatic Metastasis
1
Leukemia, Hairy Cell
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Interventions
binimetinib
2
Watchful Waiting
2
Sodium Chloride
2
Aminolevulinic Acid
2
palbociclib
1
methyl 5-aminolevulinate
1
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Trabectedin
1
Spironolactone
1
Radiotherapy
1
Radiation
1
Photochemotherapy
1
Paclitaxel
1
Low-Level Light Therapy
1
Leuprolide
1
Injections, Intradermal
1
Gonadotropin-Releasing Hormone
1
Fluorouracil
1
Floderm topical cream
1
Everolimus
1
Equipment and Supplies
1
Docetaxel
1
Dacarbazine
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Diseases
×
encorafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA